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Abstract
To assess factors influencing the success of whole genome sequencing for mainstream clinical 
diagnosis, we sequenced 217 individuals from 156 independent cases across a broad spectrum of 
disorders in whom prior screening had identified no pathogenic variants. We quantified the 
number of candidate variants identified using different strategies for variant calling, filtering, 
annotation and prioritisation. We found that jointly calling variants across samples, filtering 
against both local and external databases, deploying multiple annotation tools and using familial 
transmission above biological plausibility contributed to accuracy. Overall, we identified disease 
causing variants in 21% of cases, rising to 34% (23/68) for Mendelian disorders and 57% (8/14) in 
trios. We also discovered 32 potentially clinically actionable variants in 18 genes unrelated to the 
referral disorder, though only four were ultimately considered reportable. Our results demonstrate 
the value of genome sequencing for routine clinical diagnosis, but also highlight many outstanding 
challenges.
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Introduction
The mainstream application of whole genome sequencing (WGS) in clinical diagnosis holds 
much promise. In contrast to existing genetic tools, such as targeted gene sequencing, array 
CGH, and exome sequencing1-5, only WGS can characterise all types of genetic variant in 
all parts of the genome. Such completeness, coupled with efforts to chart the distribution of 
genetic variation in populations6,7, will enable the identification of pathogenic variants and 
hence influence diagnosis, genetic counselling and treatment.
Nevertheless, clinical adoption of WGS faces many challenges including cost, speed of 
delivery, sensitivity, specificity and heterogeneity of variant detection, ambiguities and 
errors in variant annotation, a substantial informatics burden, and the difficulties of 
incidental findings 8,9. Consequently, while technological improvements to improve speed 
in critical situations such as neonatal intensive care10 and detailed evaluations of WGS and 
whole exome sequencing (WES) in specific disorders11 are opening the opportunity for its 
wider use, its reach into the clinic is, to date, limited12. In order for WGS to be adopted as a 
routine clinical platform, we would need to demonstrate its diagnostic yield for patients with 
likely genetic disorders identified by clinicians across a broad range of medical specialties, 
within a hospital setting. Furthermore, the challenges of reliably identifying and validating 
potential pathogenic variants at scale across such a disease spectrum would need to be met.
In order to address these challenges we undertook the WGS500 programme to sequence 500 
patient genomes from diverse genetic disorders referred by a range of medical specialists. 
For all disorders, study leaders had access to additional samples and /or could follow up 
with functional studies for validation. Some results from this study have already been 
published13-19. Here, we report an overview of the results from the Mendelian and 
immunological disorders, representing 156 independent individual cases or families, 
selected because a strong genetic component was suspected (family history, early-onset, 
severe disorder) but prior genetic screening had failed to identify any pathogenic variants 
(Fig. 1). The disorders varied substantially in the number of independent cases recruited, the 
availability of additional family members and the likely disease model. Here, we identify 
and quantify the effect on success of factors relating to the genetic architecture of a disease, 
experimental design and analytical strategy.
Results
Variant calling, filtering and annotation
Individuals were sequenced to an average of 31.8× (range 22.7 – 60.8×) such that on 
average 82.7% of the genome (88.2% of the exome) was covered to at least 20× 
(Supplementary Fig. 1). We find no significant correlation between sequencing coverage 
and diagnostic success (Pearson r = −0.1, P = 0.13), indicating that, at this depth, 
fluctuations in coverage in WGS play a minor a role in determining success for germline 
disorders. For the few samples with low levels of contaminating DNA (Supplementary Fig. 
1), we took additional care over interpretation of candidate pathogenic variants rather than 
returning to the patient for additional material; one individual with substantial contamination 
was excluded.
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All samples were processed with the same pipelines for sequencing, variant calling and 
annotation (Online Methods). Concordance between the WGS data and genotypes from SNP 
arrays was over 99.9% at heterozygous sites (Supplementary Tables 1 and 2; Supplementary 
Fig. 2). Our pipeline included two key steps. First, we used a two-stage variant calling 
procedure with an initial round of independent calling followed by a second round which 
revisits the evidence in each individual for any variant called across all samples. This 
approach improves genotype accuracy by, for example, using strong evidence for a variant 
in a child to enhance support for the same variant in a parent (and vice versa). Joint calling 
substantially increases the accuracy of de novo mutation detection in families. For example, 
the number of candidate coding de novo mutations was reduced from a mean of 32.1 after 
independent variant calling (filtering against 1000 Genomes and the NHLBI Exome 
Sequencing Project, ESP) to 2.6 after joint calling of the parents and proband 
(Supplementary Table 3).
The second key step was that when identifying likely pathogenic variants, in addition to 
filtering against external data sources, we also filtered against other WGS500 samples. For 
example, when filtering against external data sources only, individuals had an average of 
80.8 rare or novel (frequency < 0.5%) homozygous coding variants, but only 1.5 if, in 
addition, variants present above this frequency in other WGS500 samples were excluded 
(Supplementary Table 4). Using control samples sequenced using the same technology and 
processed through the same pipeline reduced the impact of systematic differences between 
our studies and others in coverage, sequencing technology, experimental protocol and data 
processing (Supplementary Fig. 3, Supplementary Table 3).
Finally, we found that the choice of transcript set and annotation software can affect variant 
annotations20. Comparison of annotation using the RefSeq and Ensembl transcript sets 
revealed only 44% agreement for putative loss-of-function variants. Similarly, we found 
agreement of only 66% for loss-of-function annotations and 87% for all exonic annotations 
between the tools Annovar21 and Ensembl’s Variant Effect Predictor22. In both 
comparisons, the greatest discrepancy was for splicing annotations (agreement of 25% 
between transcript sets and 57% between software tools). Such heterogeneity in how 
variants are annotated can substantially reduce the efficacy of WGS for clinical analysis. We 
therefore used multiple annotation approaches to identify candidate variants.
Evaluating biological candidacy of variants
To identify candidate disease-causing variants we used a combination of predicted 
functional impact, frequency in the population, transmission within a family (where 
appropriate) and, when multiple independent cases were available, statistical evidence for 
association (Online Methods). Beccause most genes harbour large numbers of rare 
variants6,23 many of which are absent from existing databases and affect the protein 
produced but only a fraction of which may influence disease risk, care has to be taken in 
interpreting novel variants in known disease genes. To assess the burden of such ‘variants of 
unknown significance’ across a range of disorders we defined candidate genes for early-
onset epilepsy (EOE), X-linked mental retardation (XLMR) and craniosynostosis (CRS). 
For EOE we used a semi-automated approach on the basis of a three-tiered system according 
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to medical genetic and biological information (Online Methods; Supplementary Table 5). 
Tier 1 comprises the set of known genes for the disorder (from the Human Gene Mutation 
Database, HGMD24), Tier 2 adds genes known for related disorders (from HGMD) or 
whose products interact directly with those in Tier 1 (from the Mammalian Protein-Protein 
Interaction Database, MIPS25), and Tier 3 adds genes in relevant biological pathways (from 
HGMD and the Gene Ontology database). For XLMR we only examined Tier 1 genes. For 
CRS we used lists generated by expert curation. For those individuals with the disorder, 
additional family members were used to identify the most likely pathogenic variants 
(Supplementary Table 6).
For each disorder, we found multiple unaffected individuals in WGS500 with variants in the 
candidate genes for XLMR, CRS and EOE that would be interpreted as potentially 
pathogenic had those individuals presented with the disorder in question. Within the ten 
known genes for EOE (Tier 1), we found that 3/216 individuals (1.3% of the sample) carried 
a novel heterozygous candidate variant and one (0.5%) carried a rare homozygous candidate 
(Fig. 2a); none of these individuals had epilepsy. As the strength of gene candidacy reduced, 
the effect was increased; 36% of individuals carried at least one heterozygous candidate 
among the Tier 1 genes or the additional 82 genes implicated in milder forms of epilepsy 
(Tier 2) and 96% of individuals carried one such variant in a Tier 1 or 2 gene or in one of the 
771 genes involved in brain development or function (Tier 3). The proportions for 
homozygous candidates were 3% and 17% for Tier 1-2 and 1-3 respectively. We found no 
enrichment for either heterozygous or homozygous candidates in Tier 1-2 genes among the 
six EOE patients (Supplementary Table 7) and only 2/10 Tier 1-2 variants found in EOE 
samples are thought to be pathogenic based on family information; for homozygous variants 
in Tiers 1-3, the figure is 1/315 (Supplementary Table 6).
Similar results were found in genes for other disorders. For CRS genes, 57/216 (26%) 
samples carried at least one novel heterozygous coding variant in the 38 expert-curated 
known causative genes, though no sample had any rare homozygous coding variants 
(Supplementary Fig. 4). Five CRS samples carried Tier 1-2 variants, but none are thought to 
be pathogenic since they were not of de novo origin. For X-linked mental retardation 
(XLMR) genes, the effect is striking: 30/109 male samples (28%) carry at least one 
previously unreported missense variant at a conserved residue within the 83 known XLMR 
genes (Fig. 2b). In only two of these (two brothers with MR) was the variant thought to be 
pathogenic.
We also investigated the burden of potentially pathogenic regulatory variants, focusing on 
conserved positions in regulatory regions defined by the Ensembl Regulatory Build that are 
less than 50 kb away from candidate genes (Supplementary Fig. 5). The mean number of 
novel heterozygous variants per individual was 203 (standard deviation = 102; range 102 - 
614), more than twice as many as the equivalent number of novel coding variants (mean = 
75, Supplementary Fig. 3), although we note that this number is inflated because there are 
fewer control individuals in publicly available datasets for regulatory rather than exonic 
variants. Many individuals had novel or rare variants at conserved sites in regulatory regions 
close to candidate genes for EOE and CRS (Supplementary Fig. 6). Moreover, in samples 
from patients with the disorder, there were typically multiple potentially regulatory variants 
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that were consistent with a plausible inheritance model, although none of these are 
considered likely pathogenic because stronger candidates were present (Supplementary 
Table 6).
These results demonstrate that the combined use of gene candidacy, predicted functional 
consequence, variant frequency and evolutionary conservation, though widely used filters 
within pipelines for identifying pathogenic candidates, will not, by themselves, differentiate 
between pathogenic and non-pathogenic variants. Naïve application of such rules will lead 
to a high rate of false positive diagnosis, even in rare disorders within limited numbers of 
known genes. Moreover, focusing only on candidate genes will lead to a high false negative 
rate; of the eight EOE, CRS or XLMR families for which a strong candidate (Class A-C) for 
the pathogenic variant has been identified (Supplementary Table 6), only four of these 
variants are in candidate genes found using automated database searches (Tier 1, 2 or 3). In 
this study, as in others, additional evidence, such as functional data, familial transmission, 
de novo status and screens of other patients, was needed to establish pathogenicity.
Overview of findings
In 33 of the 156 cases (21%), we identified at least one variant with a high level of evidence 
of pathogenicity (Class A, B or C as described in Online Methods; Figure 1; Table 1; 
Supplementary Table 8). These comprised five nonsense variants, fifteen missense, three 
noncoding, two frameshifts, one in-frame indel, five variants that disrupt splicing, and two 
compound heterozygotes, each with one missense and one either nonsense or splicing 
variant (and additionally one variant that was reported independently of WGS500). 
Together, we identified twelve cases with variants in novel genes for which we found 
additional compelling genetic and/or functional evidence of pathogenicity (Class A), four 
cases with variants in genes known for other phenotypes but not for the disorder in question, 
supported by additional genetic and/or functional evidence (Class B), and seventeen cases 
with variants in genes already known for that phenotype (Class C). This rate of success is 
comparable to recent exome sequencing studies in various disorders3,5,8,26. Below we 
describe the range of the findings and some of the outstanding challenges identified.
Variants missed by prior genetic testing
We identified four cases where a candidate variant lay within a gene that had previously 
been screened by a clinical or research genetic laboratory (UK or overseas) but had been 
missed. These were variants in UMOD in familial juvenile hyperuricemic nephropathy 
(FJHN), in KCNQ1 in long QT syndrome and in APC and MSH6 in multiple adenoma. The 
rate of false negative results from Sanger sequencing is likely to vary considerably between 
genes and types of variant. Nevertheless, across the samples studied here, a relatively small 
fraction (2.5%) of cases resulted from false negative tests in standard clinical genetics 
testing.
Challenges in establishing pathogenicity
For several disorders, likely pathogenic variants were identified in genes not reported 
previously for those conditions or related phenotypes. When additional variants of major 
coding consequence were found in screens of other cases (and not controls), the evidence for 
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pathogenicity was considered strong, including for POLE and POLD1 in multiple 
adenomas/colorectal cancer19, TCF12 in Saethre-Chotzen-like syndrome16, ALG2 for 
congenital myasthenic syndrome17, and C15ORF41 in congenital dyserythropoetic anaemia, 
type 114. In some cases, mouse models provided supportive evidence (e.g. confirming the 
role of SPTBN2 in cerebellar ataxia18), and/or functional work demonstrated that the variant 
affects protein function (e.g. a KCNT1 de novo mutation found in an Ohtahara syndrome 
patient was shown to affect potassium channel activity15).
In six cases, likely pathogenic variants were identified in genes where variants cause 
disorders with related phenotypes. For example, a de novo mutation that disrupts CBL 
splicing (NM_005188:exon9:c.1228-1G>A) was identified in a patient with severe epilepsy, 
microcephaly, and developmental delay15. Cbl is a ubiquitin ligase that regulates the Ras/
MAPK pathway27,and heterozygous missense variantsin CBL cause facial, cutaneous and 
cardiac abnormalities, hypotonia and developmental delay28,29, as well as microcephaly and 
a predisposition to juvenile myelomonocytic leukemia30,31. However, whilst our patient had 
unusual cutaneous and cardiac features, these were not typical of NCFC syndrome, and 
review by clinicians did not alter the original diagnosis. CBL variants have previously been 
noted for their variable phenotypes and incomplete penetrance31. Thus, the CBL variant is a 
strong candidate, but no other likely pathogenic variants in CBL were identified in a panel of 
over 500 other epilepsy patients15.
The difficulties in establishing pathogenicity are also illustrated by a de novo missense 
mutation (NM_031407:c.329G>A:p.R110Q) in HUWE1 identified in a girl with 
craniosynostosis and learning difficulties (Fig. 3a; Supplementary Note). Mutations in 
HUWE1 are reported to cause X-linked mental retardation and macrocephaly32-34, though 
not previously CRS. The mutation affects a highly conserved residue in a domain of 
unknown function (DUF908; Supplementary Fig. 7). The gene spans 154,641 bp and 
comprises 84 exons, and, because of extensive heterogeneity in CRS, the contribution to the 
disease is likely to be low. Thus, it was not surprising that no other HUWE1 mutations were 
found in a cohort of 47 unrelated cases with complex CRS. The mutation originated on the 
paternal X chromosome (Fig. 3b; Supplementary Fig. 7). Unexpectedly, cells from the 
patient show preferential inactivation of the maternally inherited, wild-type X (Fig. 3c) and, 
consistent with these two observations, only the mutant allele was expressed in the tissues 
available (fibroblast and transformed lymphoblasts) (Fig. 3d). Seven other X-linked de novo 
point mutations (three in genes: a 5′UTR change in CCDC160 and intronic changes in 
FRMPD4 and IGSF1) were identified in the same individual (Fig. 3e), though none were 
considered pathogenic. The finding of a substitution at a highly conserved residue in a 
known XLMR gene, combined with exclusive expression of the mutant allele, suggested 
that this mutation contributed at least to the learning difficulties in this child, but that this is 
a highly unusual case, and hence it was challenging to establish true pathogenicity. 
Recently, however, we identified, using WES, a different de novo hemizygous mutation 
altering the same amino acid of HUWE1 (c.328C>T encoding p.R110W) in a boy presenting 
with metopic craniosynostosis, moderate-severe learning disability and other dysmorphic 
features, supporting the evidence for causality.
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Candidates for pathogenic regulatory variants
Strong candidate pathogenic variants were detected outside the coding fraction of the 
genome in two conditions. The same variant at a highly conserved base (chr7:100318468 
G>A; Fig. 4a) within the 5′ UTR of the erythropoietin gene EPO was identified in two 
independent families with erythrocytosis and co-segregated with the disease (Fig. 4b; 
Supplementary Note). Moreover, this is the only rare exonic variant found in an 8 Mb region 
that is identical-by-descent in the affected individuals in these two unrelated families (the 
only such region), suggesting that it had a single, and probably recent, mutational origin. 
EPO is a strong candidate gene as erythropoietin is essential for red cell production and 
increased levels cause increased red cell mass, the hallmark of erythrocytosis35,36. However, 
genetic variation in EPO has not been linked previously with erythrocytosis and further 
functional data would be necessary to prove causality definitively.
In another case, a complex event leading to deletion of 1.4 kb of the X chromosome and 
insertion of 50 kb from chromosome 2p (Fig. 4c; Supplementary Fig. 8) was discovered in a 
patient with X-linked hypoparathyroidism (Supplementary Note). This variant lies 81.5 kb 
downstream of SOX3, segregates with the disease (Fig. 4d) and is similar to an event 
reported previously in an independent kindred37. SOX3 is a strong candidate as it influences 
the development of the parathyroid gland38. Although the pathogenicity for these variants is 
not proven, that such candidates can be identified using WGS demonstrates the value of 
screening the noncoding genome.
Incidental findings
The identification of variants unrelated to the referred condition, but which have potential 
clinical and actionable significance, is a major challenge for WGS. To evaluate the burden 
of such incidental findings, we followed the American College of Medical Genetics and 
Genomics’ recommendations39 and used HGMD24 assignments of pathogenic status to 
identify 32 variants in 18 genes of possible clinical significance (four nonsense, three splice-
site and 25 nonsynonymous variants). After detailed and lengthy review of the literature and 
curated variant databases, 26 could be eliminated (Supplementary Table 9), leaving six 
variants in four genes, each present in a single case (Table 2). Although the majority of these 
variants have been published in association with a relevant disease, major doubts remain 
about their clinical interpretation due to incomplete information on (1) variant frequencies in 
large populations of healthy people, (2) phenotypes when segregating within families and 
(3) corroborative functional studies40. Where the variant occurs at significant frequency in 
public databases (e.g. the RYR1 variants), the rarity of associated case reports suggests that 
penetrance is low or indeed zero. Even in the most apparently clear-cut case of a nonsense 
variant in BRCA2, the actual disease risk is likely to be reduced in the absence of a 
documented family history41.
Any decision on clinical action must balance multiple potential harms (invasion of personal 
autonomy, the severity of proposed preventive intervention, associated healthcare costs) 
against the anticipated benefits to health. We propose that only four variants are clinically 
reportable (Table 2), whilst a further two variants are of uncertain significance and warrant 
further investigation (Table 2). For example, the R397W variant in KCNQ1 is potentially 
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associated with long QT syndrome (LQTS) and sudden death. The frequency of this single 
variant in EVS exceeds that of LQTS overall, suggesting very low absolute risk; 
nevertheless it is probably reasonable to recommend avoidance of certain classes of 
medication (even if the subject does not have any obvious ECG abnormality) as this 
intervention can, very occasionally, be lifesaving. By contrast, we do not believe that 
intensive electrophysiological investigation or clinical cascade screening of the extended 
family are indicated. These observations highlight the urgent need for unbiased data from 
large biobanks to support clinical decision making.
Discussion
The goal of the WGS500 study was to evaluate the potential value of WGS in mainstream 
genetic diagnosis. In routine clinical settings the opportunities for time-consuming 
investigation of multiple variants emerging from WGS are limited. We identified multiple 
strategies in analysis (joint variant calling, filtering of variants against local databases and 
the use of multiple annotation algorithms) that improve the reliability of variants called and 
improved sensitivity and specificity in detecting candidate disease-causing variants.
With these innovations, WGS proved to be effective for molecular diagnosis of severe 
disorders for which a strong genetic component was suspected, but where screening of 
known genes had failed previously to identify candidates. Overall, WGS identified a 
pathogenic variant in 33/156 cases (21%), 23/68 (33.8%) Mendelian cases (class A, B or C 
in category 1 or 2), increasing to 57% (8/14) in cases where de novo or recessive models 
were suspected and both parents sequenced (category 2.1) (Supplementary Table 8). The 
majority of these variants lie within genes, hence are typically accessible through WES. 
However, in an independent study of 141 exomes, 3/33 sites reported in Table 1 lay outside 
the exome target and a further six lay within the target, but had low coverage (median < 
20×; Supplementary Fig. 9). If a minimum of six reads, three of which support the variant, 
are required for detecting a novel heterozygous variant, we estimate that 15% of causal 
variants identified in this WGS study (including coding and non-coding changes) would 
likely have been missed by WES (0.5% in WGS500). Conversely, using 20 variant sites 
identified as causal from an independent exome sequencing project, we estimate that WGS 
at this coverage has 99.6% power to identify a novel heterozygous variant (compared with 
96.1% in WES; Supplementary Fig. 9).
Moreover, WGS has additional benefits. For example, in the CRS case discussed above, 
WGS was important for a) identifying the HUWE1 mutation, b) identifying nearby variants 
for establishing parent of origin, so we could subsequently show that only the mutant 
chromosome was being expressed, and c) for assessing other de novo mutations on the X 
that might affect X chromosome inactivation. The latter two points could not have been 
addressed with WES data. Moreover, WGS identified, in other cases, two likely pathogenic 
non-coding variants and unusual chromosomal features including large deletions (for 
example, a 30 Mb deletion on the X chromosome of a patient with congenital myasthenia, 
though this is not thought to be relevant to the disorder), distant consanguinity 
(Supplementary Fig. 10) and uniparental disomy (as in the case of a child with Ohtahara 
Syndrome15).
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In other types of disorder, WGS proved less successful. The number of candidate variants in 
families with dominantly inherited disorders makes functional validation time-consuming, 
and many such cases remain in active follow up. Furthermore, our hypothesis that extreme 
forms of complex disorders (young onset, severe disease) would enrich for monogenic forms 
was not confirmed. In only two cases out of 49 (one case of common variable 
immunodeficiency disorder and one in inflammatory bowel disease) did WGS on unrelated 
individuals with extreme immune-related disorders identify strong candidates for pathogenic 
variants, despite substantial sample sizes (n = 34 for CVID, n = 15 for IBD). Several other 
candidates have been identified, but pathogenicity has not been confirmed. This low success 
rate likely reflects the influence of multiple genetic factors, even in extreme cases. Only 
very large patient cohorts are well-powered for identifying novel genes with a modest 
contribution to the phenotype42,43 and, in any specific case, it will be difficult to assign 
pathogenicity to any particular variant.
Our results also highlight the outstanding challenges of WGS interpretation. Every 
individual carries multiple rare variants that could potentially be assessed as pathogenic for a 
given disorder on the basis of biological information about the gene, the coding consequence 
of the variant and its frequency within the population. Such variants may be benign, or have 
variable penetrance, making their clinical interpretation without additional information (such 
as de novo status or co-segregation with the disease within a family) challenging. 
Conversely, rigid application of biological candidacy filters will lead to false negatives. 
Ultimately, WGS will only be able to reliably assess the diagnostic and predictive value of 
any specific variant if it, or another variant in the same gene, is identified in other 
individuals with the same disorder for whom detailed phenotypic and clinical data are 
available.
Finally, the identification of pathogenic variants, exclusion of potential candidate variants 
and identification of incidental findings relied on close collaboration between analysts, the 
scientists knowledgeable about the disease and genes and clinicians expert in the specific 
disorders. The availability of resources and expertise for functional validation studies were 
critical to the assignment of causality. Provision of this network may be challenging to 
establish in a clinical setting but it will be an important aspect of successful translation of 
WGS.
Online Methods
Overview of the WGS500 Project Consortium
WGS was carried out as part of a collaboration between the Wellcome Trust Centre for 
Human Genetics at the University of Oxford, the Oxford NIHR Biomedical Research Centre 
and Illumina Inc. We sought to sequence 500 whole genomes from patients in whom 
findings could have immediate clinical utility in terms of diagnosis, prognosis, treatment 
selection, or genetic counselling and reproductive choices.
Taylor et al. Page 9
Nat Genet. Author manuscript; available in PMC 2016 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Process and criteria for sample inclusion
Proposals were invited from clinicians and researchers in Oxford, commencing in December 
2010, and were reviewed by a scientific Steering Committee. Known candidate genes and 
large chromosomal copy number changes had to have been excluded for the patient to be 
included in the study, to maximise the likelihood of identifying variants in novel disease 
genes.
Projects were categorised as follows:
1. Families with suspected Mendelian conditions with affected individuals across 
multiple generations (dominant or recessive). In these cases, we usually sequenced 
one or a few family members (chosen to maximise power for exclusion analysis) 
and obtained SNP array data on all available others, in order to identify regions 
identical by descent between affected individuals. These cases were further 
subdivided into:
1.1.1. Dominant model suspected
1.1.2. Recessive model suspected (often due to consanguinity)
1.1.3. X-linked model suspected
1.1.4. Multiple unrelated families with linkage to the same region/s
2. Families with suspected Mendelian conditions with one or more affected 
individuals in a single generation. For these, we hypothesised that they were due to 
de novo or recessive mutations. We used these sub-classifications:
2.1. Affected offspring and both parents sequenced.
2.2. Only affected offspring sequenced, not parents.
3. Cohort of unrelated sporadic patients with no known family history.
4. Individuals with extreme forms of common disorders (e.g. early onset or severe 
forms).
Ethics
Individual researchers had explicit research consent to undertake genetic investigation into 
the cause of the relevant disease, and/or samples were obtained with clinical consent as part 
of efforts to identify the cause of the patient’s disease. Ethics committee reference numbers 
for every individual research project have been provided to the journal editors.
Sequencing library Preparation
3-5 μg of DNA was obtained from each individual, usually from blood, or otherwise from 
saliva or immortalised cell lines. Samples were diluted to 80 ng/μl in 10 mM Tris-Cl, pH 
8.5, then quantified using the High Sensitivity Qubit system (Invitrogen). Sample integrity 
was assessed using 1% E-Gel EX (Invitrogen). Focused ultrasonication was carried out to 
fragment 2μg of DNA using the Covaris S2 system with the following settings: duty cycle = 
10%, intensity = 5%, cycles/burst = 200 and time = 60 s. Libraries were constructed using 
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the NEBNext DNA Sample Prep Master Mix Set 1 Kit (New England Biolabs), with minor 
modifications. Ligation of adapters was performed using 6 μl of Illumina Adapters 
(Multiplexing Sample Preparation Oliogonucleotide Kit). Ligated libraries were size-
selected using 2% E-Gel EX (Invitrogen) and the distribution of fragments in the purified 
fraction was determined using Tapestation 1DK system (Agilent/Lab901). Each library was 
PCR-enriched with 25 μM each of the following custom primers:
Multiplex PCR primer 1.0:
5′-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCT-3′
Index primer:
5′-
CAAGCAGAAGACGGCATACGAGAT[INDEX]CAGTGACTGGAGTTCAGACGTGTG
CTCTTCCGATCT-3′
Indexes were 8 bp long and formed part of an indexing system developed in-house59. Four 
independent PCRs were prepared per sample using 25% volume of the pre-PCR library 
each. After 8 cycles of PCR (cycling conditions as per Illumina recommendations) the four 
reactions were pooled and purified with AMPure XP beads (Beckman Coulter, Inc.). The 
final size distribution was determined using a Tapestation 1DK system (Agilent/Lab901). 
The concentration of each library was determined by Real-time PCR using the Agilent 
qPCR Library Quantification Kit and an MX3005P instrument (Agilent).
Whole genome sequencing and quality control
WGS was performed on either the Illumina HiSeq2000 or the HighSeq2500 run in standard 
mode, either by the Oxford Genomics Centre at the Wellcome Trust Centre for Human 
Genetics, or by Illumina Cambridge Ltd.. We generated 100 bp reads and used v2.5 or v3 
clustering and sequencing chemistry. A PhiX control was spiked into the libraries. We 
aimed for a mean coverage of 30× and obtained a minimum of 22.7×. The mode number of 
lanes required to reach the desired coverage was 2⅓.
We used the recommended quality metrics in the Illumina Sequence Analysis Viewer in 
analysing each lane. Additionally, we generated our own quality metrics for each lane (or, in 
the case of multiplexes, each part of a lane), and required the following criteria to be met: 
<2% duplicate pairs; most frequent kmer <2%; >99% mapped; <2.5% read pairs mapping to 
different chromosomes; mean insert size between 340 bp and 440 bp, with a median 
absolute deviation of <30bp; approximately uniform genomic coverage by GC content; ~1% 
exonic coverage; <2% N bases at any cycle; approximately equal number of reads per tag 
(three samples multiplexed per lane), standard deviation <25%.
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Read mapping
Sequence reads were generated using the Illumina offline basecaller (OLB; v1.9.3) and 
mapped to the GRCh37d5 human reference sequence. This reference genome was obtained 
from the 1000 Genomes Project and is based on hg19 but contains a 35.48 Mb decoy 
chromosome that reduces misalignment of repetitive sequence and improves accuracy of 
SNP discovery. Mapping was performed using BWA (v0.5.6)60 and Stampy (versions 1.0.12 
- 1.0.22; see URLs)61, and merging and deduplication using Picard (v1.67; see URLs).
SNP and indel calling and genotyping
Variant calling was performed with Platypus62 (version 0.1.9; see URLs) using the default 
settings. This algorithm can detect SNPs and short indels (<50 bp), and is sensitive to 
somatic mosaic mutations at low allele frequencies63,64.
The variant calling included two stages. First, we used Platypus to identify SNPs and short 
indels in all samples individually (raw calling). We then ran it a second time to genotype the 
union of all variants in all samples. We did the raw calling on groups of related samples 
together (“joint calling”), so that the same sites were interrogated for all samples in the 
family (i.e. it was possible to distinguish homozygous reference from a missing call), and so 
that the observation of a variant in one of the individuals in the family reduced the required 
threshold for calling it in the others (see Rimmer, et al. 62).
We retained variants with a PASS flag that had a posterior probability (phred scale) of >20 
that the variant segregates. Variants with a “clustered” flag (within 25 bp of another variant) 
were manually checked in IGV65 but not discounted.
To check for sample contamination, we plotted the distribution of the ratio of the number of 
reads containing the alternate allele to the total number of reads (ALT:TOTAL) for known 
SNPs (from dbSNP) and novel SNPs for each sample (Supplementary Figure 1D). To check 
for duplicates and cryptically related individuals, we ran principal components analysis on 
the WGS500 data. We included the three ethnic groups (CEU, YRI and JPT/CHB) from the 
HapMap project, which allowed us to identify a few individuals with a particularly high 
number of variants as ancestry outliers.
Filtering variants in trios
There were fifteen families in WGS500 from which both the parents and one or more 
affected children were sequenced: six trios and one quartet with early-onset epilepsy (EOE), 
a trio with hypertrophic cardiomyopathy (HCM), a trio with erythrocytosis (ERY) (with 
mother and daughter affected), four trios with craniosynostosis (CRS), a trio with Saethre-
Chotzen syndrome (SC; a type of CRS), and a quartet with X-linked mental retardation 
(XLMR). If the parents were unaffected and only one child was affected, the initial 
hypothesis was that the causal mutation was de novo. To screen for these variants, we 
searched for variants that were absent from all public databases (1000 Genomes, dbSNP, 
ESP) and from other WGS500 samples, and that had been confidently called as 
heterozygous in the child and as homozygous reference in the parents (genotype log 
likelihood ratio, GLLR < −5). (This latter criterion on the GLLR was not always applied 
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when analyzing data for specific projects.) Supplementary Table 3 demonstrates the value of 
applying these different filters.
We also investigated a simple recessive model in these families. Homozygous variants in the 
affected child (or children) had to have a frequency less than 0.5% in 1000 Genomes and 
ESP (corresponding to an expected homozygous frequency of 1 in 40,000), and there had to 
be 0 homozygotes and ≤ 2 heterozygotes amongst the unrelated WGS500 samples. We 
required the parents to be called as heterozygous. Results of these filters are shown in 
Supplementary Table 4. When filtering for compound recessive candidates (in which the 
child had two rare heterozygous coding variants in the same gene, one inherited from each 
parent) and X-linked recessive candidates, we used the same frequency thresholds as for the 
simple recessive case.
Annotation of variants
The functional consequences of variants were predicted using several programmes. We used 
ANNOVAR (February 2013 version)66 to annotate variants with respect to RefSeq genes, 
adding information about segmental duplications, conservation (based on the UCSC 
alignment of 46 mammalian genomes), GERP, SIFT, MutationTaster, phyloP and 
PolyPhen2 scores, dbSNP identifiers (version 1.35), and frequency in the NHLBI Exome 
Sequencing Project (see URLs) and Phase 1 of the 1000 Genomes Project 6. We also 
annotated all variants using the Variant Effect Predictor from EnsEMBL (version 69) and 
the nonsynonymous SNPs using PolyPhen2 (version 2.2.2r405).
Detection of copy number variants and extended homozygosity
We used several different methods to search for copy number variants (CNVs). 1) We 
generated count profiles for each individual by dividing each chromosome into 10 kb bins 
and counting number of reads in each bin. For each chromosome, we applied principal 
components analysis to the log of the counts (training set - one per family), and then plotted 
the residuals of the predicted PCs along the chromosome. This procedure served to remove 
noise in the data due to biases in sequence composition. Candidate CNVs (down to about 10 
kb) were identified as outliers visually. 2) We applied OncoSNP-SEQ67 in germline mode to 
a subset of 300,000 reliable SNPs across the genome. Coverage and read counts at these 
locations were used as proxy for the intensity and B-allelic-frequency under a specific model 
of the Hidden Markov Model intended for next-generation sequencing data. 3) To identify 
exon-level CNVs, we used ExomeDepth68.
To search for long regions of homozygosity (LROHs), we calculated the fraction of 
heterozygous SNPs in 10 kb bins along the chromosomes for each individual, averaged 
these over 1 Mb regions, and plotted them, ignoring centromeric and other repetitive 
regions. We classed as “homozygous” any segments with a heterozygous/homozygous ratio 
< 0.2; this empirically chosen threshold avoided large homozygous regions being interrupted 
by genotyping errors in difficult regions, but clearly distinguished them from the rest of the 
genome. Homozygous regions up to 4 Mb size are common in demonstrably outbred 
individuals69. Consanguinity had already been reported for many of the thirty-nine 
individuals who had LROHs larger than 4 Mb (Supplementary Figure 10), but in cases for 
Taylor et al. Page 13
Nat Genet. Author manuscript; available in PMC 2016 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
whom it had not, this finding prompted analysts to search for rare homozygous variants 
within these regions.
SNP array data
Illumina SNP arrays were run on some WGS500 samples and other relatives. This was to 
check the genotyping accuracy of our sequencing pipeline, to refine linkage regions, to 
confirm familial relationships, and, in two cases, to investigate whether large stretches of 
homozygosity were likely due to uniparental disomy or unreported consanguinity. We ran 
200 ng of DNA on the Illumina Human CytoSNP12 array or on the 1M array (Illumina 
Inc.), following the manufacturer’s guidelines. Concordance between the CytoSNP12 
genotypes and the WGS data is shown in Supplementary Tables 1 and 2, and the 
dependence on coverage in Supplementary Figure 2. In most cases, array-CGH had already 
been performed prior to submission of samples, but we also used QuantiSNP70 to check for 
CNVs, as well as Nexus Copy Number version 7 (BioDiscovery, Hawthorn, CA). We used 
MERLIN71 in familial studies to identify regions identical-by-descent.
Assessment of coverage in WGS500 and exome sequence data
After removing duplicate reads, we used bedtools72 to measure coverage in all WGS500 
samples, and examined the cumulative distributions across the genome and exome (CCDS 
transcripts) (Supplementary Figure 1A,B). In order to compare this with a typical exome 
sequencing experiment, we took 141 whole exome datasets that had been captured using the 
Roche Nimblegen SeqCap EZ v.2.0 kit at the Oxford Biomedical Research Centre, removed 
duplicate reads, and measured coverage at each position in the CCDS transcripts. We 
compared the exome-wide coverage distributions between WGS500 and these exomes 
(Supplementary Figure 1), as well as the coverage at specific variants thought to be causal 
(Supplementary Figure 9).
Identifying variants of clinical relevance
Following variant calling and annotation, cases from specific projects were investigated by 
different analysts, and variants prioritised on the basis of mode of inheritance, functional 
consequence, population frequency, evolutionary consequence of position and biological 
relevance. Where available, parental data, linkage information and repeated occurrence 
across multiple independent cases with a disorder were used to aid prioritisation. Validation 
of biological consequence and/or screening of additional cohorts was used to confirm 
pathogenicity. Where a previously described variant or variant class (e.g. loss of function, 
frameshift) was observed in a known gene for a disorder, it was assumed to be pathogenic 
and missed by prior screening. All putatively causative variants were confirmed using 
Sanger sequencing. Information was returned to clinicians responsible for managing 
individual patients, who decided whether and how information was reported to them.
Classification system for results
We categorised the results for each independent case into five classes, as follows:
• Class A: Mutation found in a novel gene, with additional genetic evidence (in 
unrelated cases) and/or functional data supporting causality.
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• Class B: Mutation found in a gene known for a different phenotype, with additional 
genetic evidence and/or functional data supporting causality.
• Class C: Mutation found in a known gene for this phenotype.
• Class D: Mutation found in a novel gene, with further genetic and functional 
validation studies in progress.
• Class E: No single candidate yet, or negative results for validation of original 
candidates.
The results for all projects are summarised in Figure 1. Note that one of the CVID cases 
recovered antibody production, and was thus found to have been misdiagnosed.
Analysis of gene/variant tiering strategy
For eight of the thirteen families mentioned above from which we sequenced the affected 
child/children and healthy parents, we have identified the causal mutation with a reasonable 
level of confidence (class A, B or C in Supplementary Table 6). Thus, we used these 
families as test cases for the analysis in this section.
We compiled tiered lists of candidate genes for each of the three diseases: EOE, CRS and 
XLMR. For EOE (Supplementary Table 5), Tier 1 contains genes that are recorded in the 
Human Gene Mutation Database (HGMD)24 as causing Ohtahara syndrome or epileptic 
encephalopathy, Tier 2 contains genes that interact with Tier 1 genes (according to the 
Mammalian Protein-Protein Interaction Database (MIPS) database25) or that are listed in 
HGMD as causing more general epilepsy, and Tier 3 contains genes that are involved in 
biological pathways known to be involved in pathogenesis. For CRS, Tier 1 is a hand-
curated list of genes mentioned in the literature as causing CRS in two or more cases, Tier 2 
is a list of additional genes associated with the term “craniosynostosis” in the the 
Copenhagen disease gene association list (see URLs), and Tier 3 comprises additional 
orthologs of 270 mouse genes that are expressed in the skull73 (Eurexpress database; see 
URLs). For XLMR, we compiled the Tier 1 list by searching HGMD for “mental 
retardation” and “intellectual disability” and then restricting to chrX; we did not consider 
additional tiers since Tier 1 already contained 83 genes.
We analysed the mutational burden in these genes for all 216 samples, having excluded the 
contaminated sample HCM_2361 (Supplementary Figure 1. Specifically, we screened for 
coding variants in these genes that would appear to fit a de novo dominant (DN), simple 
recessive (SR) or X-linked (XL) model in the absence of parental information, according to 
the following criteria:
• De novo model: novel variant heterozygous in proband and absent from 1000 
Genomes, ESP and other unrelated WGS500 samples
• Simple recessive model: novel or very rare variant homozygous in proband, 
frequency <0.5% in 1000 Genomes and ESP, with no other homozygotes and ≤ 2 
heterozygotes amongst the unrelated WGS500 samples
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• X-linked recessive model: novel or very rare variant hemizygous in male proband, 
frequency <0.5% in 1000 Genomes and ESP, and no other homozygous females or 
hemizygous males and ≤ 2 heterozygotes amongst the unrelated WGS500 samples
A variant was considered “coding” if it was annotated by ANNOVAR66 as missense, stop 
gain or stop loss, an indel, or within a splice site, for one or more transcripts, and 
“conserved” if it had a GERP or phyloP score greater than 2, or was in a constrained 
element as defined by the UCSC 46-way alignment. We also used VEP to add information 
about regulatory regions from the Ensembl V65 Regulatory Build (see URLs).
Actionable, pathogenic incidental findings
We followed the guidelines of the American College of Medical Genetics and Genomics39 
for reporting incidental findings. To identify potentially disease-causing mutations, we first 
took all the mutations in HGMD24, left-aligned the indels, and removed variants with 
erroneous reference alleles. We retained those classed as “DM” (disease mutation) that were 
within 10 bp of an exon of a gene in Table 1 of Green et al.39. We then searched all 
WGS500 samples for these mutations, and for nonsense or frameshift mutations in the same 
genes, which would be expected to be pathogenic. We removed any variants with a 
frequency >1% in 1000 Genomes or the Exome Variant Server. Variants that were i) 
classified as variants of unknown significance in curated, disease-specific mutation 
databases ii) had high frequency in Exome Variant Server iii) had negative functional data 
iv) showed lack of segregation in literature reports or v) were unlikely to be of significance 
from their sequence context (e.g. splicing variants without clear splicing signatures) were 
removed. These are listed in Supplementary Table 9. The remaining variants (Table 2) were 
then scrutinized by a panel of clinical experts, who decided which variants had enough data 
supporting pathogenicity to report.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overview of projects and results
For each disorder, the number of independent cases (bars) studied is shown alongside 
information about the nature of the disorder: familial disorders (category 1, light green 
triangles), severe single-generation disorders suspected to be caused by de novo or recessive 
mutations (category 2, dark green), unrelated sporadic disorders (category 3, light blue) and 
extreme cases of common complex diseases (category 4, dark blue). The proportion of cases 
with each outcome class A-E is also shown (see Online Methods): pathogenic variant in 
novel gene for disorder (A, red circles), pathogenic variant in gene for related disorder (B, 
brown), pathogenic variant in known gene for disorder (C, pink), candidate pathogenic 
variant with validation studies underway (D, orange) and no single candidate variant, or 
negative results for validation of top candidate/s (blue). Size of points proportional to 
outcome fraction. Disorders are ranked by fraction of cases with confirmed pathogenic 
variants (class A to C).
Taylor et al. Page 23
Nat Genet. Author manuscript; available in PMC 2016 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2. The burden of variants of unknown significance
(a) Histograms of the number of previously unreported coding variants at conserved 
positions in different sets of candidate gene (Tiers 1, 1+2 and 1+2+3 for columns left to 
right) for early-onset epilepsy, under different inheritance models, across 216 WGS500 
samples. (b) Histogram of the number of previously unreported coding variants at conserved 
positions in known X-linked mental retardation genes (XLMR), for the 99 male WGS500 
samples. The candidate genes were chosen by high-throughput searches (Online Methods). 
Sample identifiers indicate individuals with the disorder in question. Sample names in green 
text indicate that the variant is not likely to be pathogenic (since it does not fit a plausible 
inheritance model or is less functionally compelling than another candidate); blue text 
indicates that the variant is thought to be causal (see Supplementary Table 6). OTH: 
Ohtahara syndrome; EOE: nonsyndromic early onset epilepsy; MR: mental retardation. See 
Supplementary Fig. 4 for the analysis of craniosynostosis.
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Figure 3. Identification of de novo HUWE1 mutation associated with severe craniosynostosis
(a) Upper panel, the proband (CRS_4659; female, aged 6 months) presented with an 
abnormal skull shape. Lower panel, three-dimensional CT scan aged 5 months shows 
multisuture synostosis with multiple craniolacunae. (b) Family pedigree showing dideoxy 
sequence chromatograms with de novo G>A mutation of the X-linked HUWE1 gene in the 
proband (red arrow). Schematic X chromosomes are annotated from top to bottom with the 
HUWE1 alleles, haplotype of AA/CC polymorphisms located 1.15 kb away from mutation 
and used to deduce paternal origin, and androgen receptor (AR) trinucleotide repeat allele 
size (allele sizes in CRS_4654 and CRS_5215 are in brackets to emphasize that phase is 
unknown relative to other parts of the two X chromosomes). Note that the HUWE1 mutation 
abolishes a HpaII restriction site. (c) Analysis of X-inactivation in whole blood samples at 
AR locus. For each individual, AR alleles are indicated by arrows in the upper panel, while 
the lower panel shows proportions of methylated alleles and percentage representation of the 
more highly inactivated X chromosome. (d) Exclusive expression of cDNA from the 
HUWE1 mutant allele in both fibroblast (Fib) and Epstein Barr virus (EBV)-transformed 
lymphoblastoid cells from the proband. Arrows highlight absence of expression of the 
normal allele in either cell type. Product sizes (bp) from different alleles are shown on the 
right. WT: wild-type, Mut: mutant. (e) X chromosome ideogram showing eight de novo 
mutations identified. Where known, the parental allele on which the variant arose is 
indicated.
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Figure 4. Candidate pathogenic noncoding variants
(a) Multi-species alignment of a region of the 5′ UTR of EPO in which a variant was 
identified at a conserved position (red text) in two families with erythrocytosis. (b) 
Erythrocytosis pedigrees studied, showing affected individuals (shaded grey), those 
sequenced (red borders), and genotypes of all individuals for whom we had DNA. We had 
no information about the father of PAR09 (dotted box).(c) Summary of read mapping in an 
individual with hypoparathyroidism showing evidence for an interstitial insertion-deletion 
event in which a ~ 50 kb region of chromosome 2p25.3 (top panel) has been duplicated and 
inserted into chromosome X, resulting in a 1.4 kb deletion 81.5 kb downstream of SOX3 
(bottom panel). Yellow reads: mate maps to chrX; red reads: mate maps to chr2; grey reads: 
read and mate map to the same chromosome; white reads: read has mapping quality 0. (d) 
Pedigree showing segregation of the complex variant within the affected pedigree, with PCR 
validation below. M: mutation; N: normal. Primers 2SPF and XSPR flank the distal 
breakpoint of the deletion-insertion and are shown in Supplementary Figure 8. Primers 
XSPF and XSPR detect the normal allele. The mutation was not seen in 150 alleles from 100 
unrelated normocalcemic individuals (50 males and 50 females, including N1 and N2, who 
are shown).
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Table 1
Summary of conditions for which pathogenic genes were identified (class A, B or C)
Disease Project category Result class Genea Coding consequence Inheritance (Zygosity)b Variant
Acquired essential
thrombocytosis 1.1 C THPO splicing D (het) NM_001177598: c.13+1G>C
Asplenia 2.2 C RPSAc splicing D (het) NM_002295.4:c.-34+5G>C
Cerebellar ataxia 1.2 B SPTBN2 nonsense AR (hom) NM_006946:c.1881G>A:p.C627*
Common variable
immunodeficiency disorder 3 C
d missense d d
Congenital dyserythropoietic
anaemia, type 1 1.2 A C15ORF41 missense AR (hom) NM_001130010:c.533T>A:p.L178Q
Congenital myasthenic syndrome 3 B ALG2 missense AR (hom) NM_033087:c.203T>G:p.V68G
Craniosynostosis
2.1 A ZIC1 nonsense DN (het) NM_003412.3: c.1163C>A: p.S388*
2.1 B HUWE1 missense DN (het) NM_031407.6: c.329G>A:p.R110Q
Erythrocytosis
1.1 A EPO noncoding D (het) NM_000799.2:c.-136G>A
1.1 A EPO noncoding D (het) NM_000799.2:c.-136G>A
3 C BPGM missense D (het) NM_001724:c.269G>A:p.R90H
Familial hypoparathyroidism
1.3 C SOX3 noncoding XL (hemi) deletion of chrX:139,502,946-139,504,327,1.5kb downstream of SOX3
1.1 C CASR missense D (het) NM_000388:c.2299G>C:p.E767Q
Familial juvenile hyperuricaemic
nephropathy 1.4 C UMOD missense D (het) NM_001008389:c.410G>A:p.C137Y
Familial tubulo-interstitial
nephropathy 1.1 C UMOD missense (inframe insertion/deletion) D (het)
NM_001008389:c.279_289del:p.93_97del;
NM_001008389:c.278_279insCCGCCTCC:p.V9 3fs
Hypertrophic cardiomyopathy 
(sarcomere gene-negative) 1.1 C MYBPC3 nonsense e NM_000256:c.1303C>T:p.Q435*
Inflammatory bowel
syndrome/colitis 4 A
d missense d d
Interstitial nephritis 1.4 C MUC1c - D (het) d
Long QT syndrome 1.1 C KCNQ1 missense D (het) NM_000218:c.1195_1196insC:p.A399fs
Mental retardation 2.1 C GRIA3 missense XL (hemi) a
Ohtahara syndrome and other
early-onset epilepsies
2.1 A PIGQ splicing SR (hom) NM_004204:c.690-2A>G
2.1 B KCNT1 missense UPID (hom) NM_020822: c. 2896G>A:p.A966T
2.1 C KCNQ2 missense DN (het) NM_004518:c.827C>T:p.T276I
2.1 C SCN2A missense DN (het) NM_001040143:c.5558A>G:p.H1853R
Multiple adenoma
1.1 A POLD1 missense D (het) NM_002691:c.1433G>A:p.S478N
1.1 A POLD1 missense D (het) NM_002691:c.1433G>A:p.S478N
4 A POLE missense D (het) NM_006231:c.1270C>G:p.L424V
4 C MSH6 missense and nonsense CR (het; het) NM_000179:c.2315G>A:p.R772Q
4 C BMPR1A frameshift AR (hom) NM_004329.2:c.142_143insT:p.Thr49Asnfs*2 2
4 C APC splicing D (het) NM_001127511:c.251-2A>G
Saethre-Chotzen syndrome
(TWIST1 negative)
3 A TCF12 nonsense DN (het) NM_207037.1:c.1283T>G; p.L428*
3 A TCF12 splicing DN (het) NM_207037.1:c.1035+3G>C
2.1 A CDC45 synonymous (splicing) and missense CR (het; het) NM_001178010.2:c.318C>T;p.V106=;NM_001178010.2:c.773A>G;p.D258G
a
Each line represents a separate case or family, so if the same gene is reported on two lines, this signifies that the gene is thought to be pathogenic 
in both cases. Some genes have two mutations in the same affected individual, likely representing compound heterozygous inheritance, which is 
indicated in the Inheritance column.
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b
D(het): dominant - affected individual/s heterozygous; AR (hom): autosomal recessive – affected individual/s homozygous; DN (het) :de novo – 
affected individual/s heterozygous; XL (hemi): X-linked recessive – affected male/s hemizygous, affected female/s homozygous; UPD (hom): 
uniparental isodisomy–affected individual homozygous; CR (het; het): compound recessive – affected individual /s heterozygous for two different 
variants in the same gene
cCausal variant discovered independently of WGS500.
d
Details will be reported in an independent publication.
e
Form of inheritance not clear. See Supplementary Table 8.
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Table 2
Incidental findings with potentially actionable consequences
Incidental finding condition Gene AA change UK10K EVS_EA Comments
I. Reportable Incidental Findings
Arrhythmogenic right 
ventricular cardiomyopathy 
(ARVC)
DSG2 NM_001943: c.2397T>G:p.Y799* absent absent Stop gain mutation, not previously 
reported, but mutation class considered 
pathogenic44
DSG2 NM_001943: c.2554G>T:p.E852* absent absent As above
Breast & ovarian cancer BRCA2 NM_000059: c.7558C>T:p.R2520* absent 0.0001 Stop gain mutation; 5 independent R2520* 
in affected patients45-49. 4 reports of 
variant being pathogenic in ClinVar50 
(submitted by independent clinical labs) 
and 7 records rated as causal in UMD-
BRCA2 database51. Mutations of this class 
described in Brohet, et al. 52.
Long QT syndrome KCNQ1 NM_000218: c.877C>T:p.R293C absent absent 2 independent reports in literature: i) 4 /
2500 independent cases from FAMILION 
cohort referred for LQT genetic testing53 
and ii) 1 case /388 consecutive unrelated 
patients with swimming triggered 
arrhythmia syndromes54, as compound 
heterozygote with G269D. Location of 
mutation in pore suggestive of 
pathogenicity.
II. Incidental Findings of Uncertain Significance
Long QT syndrome KCNQ1 NM_000218: c.1189C>T:p.R397W absent 0.0006 3 independent reports in literature, 
including 3/2500 independent cases 
referred for long QT testing55, 5/600 cases 
in LQT registry53 and 1/91 independent 
cases of intrauterine foetal death56. 
Functional data from heterologous 
expression of mutation i) in HEK293 cells 
which shows markedly reduced current on 
whole cell patch clamp compared with 
WT56 and ii) in inside-out membrane 
patches from Xenopus oocytes which 
showed markedly reduced ATP binding57. 
Taken together, this suggests that the 
mutation should not be disregarded 
clinically as it may be weakly pathogenic, 
albeit with low absolute risk
Malignant hyperthermia RYR1 NM_000540: c.5036G>A:p.R1679H 0.0006 0.0014 Variant observed in single subject with 
complication, and positive functional 
testing58 but no independent replication.
Variants deemed to be reportable and clinically actionable are listed Section I of the table. Those for which the evidence was not considered 
sufficient to be clinically actionable are reported or are uncertain are listed in Section II.
AA: amino acid; VUS: variant of unknown significance; UK10K: frequency in the UK10K twin cohort; EVS: Exome Variant Server; EVS_EA: 
frequency in European Americans in the EVS; HGMD: Human Gene Mutation Database; UMD: Universal Mutation Database (see URLs).
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